Mutations that cause esophageal adenocarcinoma (OAC) have been mapped in unprecedented detail — unveiling that more than half could be targeted by drugs currently in trials for other cancer types.
Mapping esophageal cancer genes leads to new drug targets
Mutations that cause esophageal adenocarcinoma (OAC) have been mapped in unprecedented detail — unveiling that more than half could be targeted by drugs currently in trials for other cancer types.